| Bioactivity | Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes[1]. |
| CAS | 144412-49-7 |
| Formula | C24H28N4O6 |
| Molar Mass | 468.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Moliterno DJ, et al. Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study. J Thromb Thrombolysis. 1995;2(3):165-169. |
Lamifiban
CAS: 144412-49-7 F: C24H28N4O6 W: 468.50
Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination w
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.